Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 19OTHER 12NIH 3NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Lymphoma, T-Cell, Cutaneous 1

Interventions

Radiotherapy 302Cisplatin 266Cyclophosphamide 230Doxorubicin 177Paclitaxel 170Vincristine 162Carboplatin 152Filgrastim 140Etoposide 139Gemcitabine 118Docetaxel 114Fluorouracil 113Methotrexate 106Dexamethasone 106Cytarabine 106Prednisone 92Leucovorin 90Gene Expression Profiling 82Granulocyte Colony-Stimulating Factor 75Specimen Handling 70Magnetic Resonance Spectroscopy 63Irinotecan 59Capecitabine 59Radiation 54Polymerase Chain Reaction 51Ifosfamide 51Rituximab 49Immunohistochemistry 49Daunorubicin 49Oxaliplatin 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × mogamulizumab × Clear all
NCT04128072 2024-04-05

MOGAT

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Recruiting
43 enrolled
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡